Home › Cancro ovarico › New York

Studi clinici su Cancro ovarico nello stato di New York

96 studi su Cancro ovarico cercano partecipanti presso sedi nello stato di New York.

Città nello stato di New York

Testo ufficiale dello studio (inglese)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
e altri 8

In reclutamentoFase 2

Tutte le età · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Columbia University Medical Center, New York
Memorial Sloan Kettering, New York

In reclutamentoFase 1/2

Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
Icahn School of Medicine at Mount Sinai, New York
e altri 2

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

START New York Long Island LLC, Lake Success

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06270706

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

SUNY Upstate Medical University - Syracuse /ID# 277305, Syracuse

In reclutamentoFase 2

Età 18 e oltre · Donne · Aggiornato il 1 ott 2026 · NCT07024784

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Roswell Park Cancer Institute IDS, Buffalo
Memorial Sloan Kettering Hospital, New York

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06172478

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Kings County Hopsital Center, Brooklyn
Queens Cancer Center of Queens Hospital, Jamaica
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York
e altri 1

In reclutamento

Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT04751435

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NYU Longone Health (Long Island), Long Island City
NYU Longone Health (Manhattan), Manhattan

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06799065

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, New York

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT05877599

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Site 0126 - Wilmot Cancer Center, Rochester

In reclutamentoFase 2

Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT05128825

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Mount Sinai Health System, New York
Memorial Sloan Kettering Cancer Center, New York

In reclutamento

Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT05287451

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Imbert Cancer Center /ID# 275634, Bay Shore
Northwell Health Cancer Institute At Huntington /ID# 276814, Greenlawn
Northwell Health Center for Advanced Medicine. /ID# 275641, Lake Success
e altri 2

In reclutamentoFase 2

Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT06890338

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

The Woman's Health Pavilion, Howard Beach
The Woman's Health Pavilion, Westbury

In reclutamentoStudio osservazionale

Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT05051722

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site, Mineola
Avenzo Therapeutics Recruiting Site, New York

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05867251

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NYU Langone Medical Center, New York

In reclutamentoStudio osservazionale

Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT04981119

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 1/2

Età 18 e oltre · Donne · Aggiornato il 25 set 2026 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 1/2

Età 18 e oltre · Donne · Aggiornato il 24 set 2026 · NCT04590326

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site, Commack

In reclutamentoFase 2

Età da 18 a 130 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05489211

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Columbia University, New York
NYU Langone Health, New York
Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Columbia University Medical Center /ID# 277990, New York
SUNY Upstate Medical University - Syracuse /ID# 277245, Syracuse

In reclutamentoFase 2

Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Roswell Park Cancer Institute, Buffalo
Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
e altri 3

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

New York University (NYU) Clinical Cancer Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213791

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Memorial Sloan Kettering Cancer Center Head Neck Services, New York

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT05983432

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT04752826

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Womens Cancer Care Associates, LLC ( Site 0023), Albany
Memorial Sloan Kettering Cancer Center ( Site 0072), New York

In reclutamentoFase 3

Età 18 e oltre · Donne · Aggiornato il 17 set 2026 · NCT07318558

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

Roswell Park Comprehensive Cancer Center, Buffalo

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07489287

A Study of Isoquercetin in People With Ovarian Cancer

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
e altri 1

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT07303894

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Laura and Isaac Perlmutter Cancer Center, New York
State University of New York Upstate Medical Unive, Syracuse

In reclutamentoFase 2

Età da 18 a 99 · Donne · Aggiornato il 15 set 2026 · NCT07023627

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Mount Sinai, New York

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06303505

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

NYU Langone Health, Mineola
Columbia University Medical Center, New York

In reclutamentoFase 3

Età 18 e oltre · Donne · Aggiornato il 14 set 2026 · NCT04575935

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Research Site, Commack

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT05123482

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NYU Langone Health - Long Island, Mineola
New York University (NYU) Clinical Cancer Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NYU Langone Hospital - Long Island ( Site 0015), Mineola
Laura and Isaac Perlmutter Cancer Center ( Site 0076), New York

In reclutamentoFase 3

Età 18 e oltre · Donne · Aggiornato il 3 set 2026 · NCT06824467

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

Start Nyli, New York

In reclutamentoFase 1/2

Età 18 e oltre · Donne · Aggiornato il 1 set 2026 · NCT07736937

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

New York Cancer & Blood Specialists, New York
University of Rochester - Wilmot Cancer Institute, Rochester

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06582017

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07186842

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Stony Brook Cancer Center, Stony Brook

In reclutamentoFase 3

Età 18 e oltre · Donne · Aggiornato il 26 ago 2026 · NCT05281471

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Northwell Health Cancer Institute at Huntington, Greenlawn

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT04329494

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Icahn School of Medicine at Mount Sinai, New York
Montefiore Einstein Comprehensive Cancer Center, The Bronx

In reclutamentoFase 1

Età 15 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT06276491

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.